semaglutide tablets patent expiry launch date The upcoming of the in India in mid-March 2026 is Novo Nordisk and D Young

568 drugs are actively in development

Heeringa is a Board certified General Surgeon, a Fellow of the American College of Surgeons, and a Diplomate of the American Board of Venous and Lymphatic Medicine

A small 2026 pilot reported greater blood exposure for one proprietary formulation than for standard glutathione

Some patients notice enhanced appetite control due to Mounjaros dual mechanism

Liver problems among Americans impact over a third of the population

Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected as new entrants including Boehringer Ingelheim, Amgen, Pfizer and Roche offer novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly)